Bragar Eagel & Squire, P.C. Is Investigating Agrify, Cronos, Everbridge, and CareDx and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Agrify Corporation (NASDAQ: AGFY), Cronos Group, Inc. (NASDAQ: CRON), Everbridge, Inc. (NASDAQ: EVBG), and CareDx, Inc. (NASDAQ: CDNA). Our investigations concern whether these companies have violated the federal securities laws andor engaged in other unlawful business practices. Additional information about each case can be found at the link provided.

Agrify Corporation (NASDAQ: AGFY)

On December 16, 2021, during trading hours, market analyst Bonitas Research published a report regarding Agrify which alleges several issues at the Company including that "[w]e believe that Agrify created artificial demand for its product by financing undisclosed Company insiders to act as independent customers." Further the report alleges that "Agrify insiders lied to investors about the independence of its customer base in order to execute a dubious stock promotion for self-enrichment at the expense of minority shareholders[,]" and that "[e]vidence showed that five (5) of Agrify's eight (8) customer announcements in 2021 are either with undisclosed Company insiders or with unlicensed unproven operators."

On this news, Agrify's common stock price fell sharply during intraday trading on December 16, 2021.

For more information on the Agrify investigation go to: https://bespc.com/cases/AGFY

Cronos Group, Inc. (NASDAQ: CRON)

On November 9, 2021, Cronos filed a Form 8-K with the U.S. Securities and Exchange Commission, stating that "[o]n November 8, 2021, Cronos Group Inc. . . . determined that it will be required to restate its previously issued unaudited interim financial statements for the three and six months ended June 30, 2021 previously filed on Form 10-Q on August 6, 2021" and advising that "[t]he Company's financial statements for this period should therefore no longer be relied upon." Cronos further stated that "[t]he Company concluded that it should have recorded an impairment charge of not less than $220 million on goodwill and indefinite-lived intangible assets in its U.S. reporting unit for the three and six months ended June 30, 2021. The Company will restate its unaudited interim financial statements for the three and six months ended June 30, 2021, accordingly." According to Cronos, the Company "is also evaluating whether to record an additional impairment in the three and nine months ended September 30, 2021."

On this news, Cronos's stock price fell $1.01 per share, or 15.05%, to close at $5.70 per share on November 9, 2021.

For more information on the Cronos Group investigation go to: https://bespc.com/cases/CRON

Everbridge, Inc. (NASDAQ: EVBG)

On December 9, 2021, after the market closed, Everbridge announced that CEO David Meredith resigned. Bloomberg reported analyst Stifel as stating, "[t]he timing and uncertainty around the circumstances of Mr. Meredith's departure combined with the company's guidance introduces a high degree of uncertainty into the story" and that there are "more questions than answers at this point."

Following this news, Everbridge shares fell $52.37 per share, over 45%, to close at $63 per share on December 10, 2021.

For more information on the Everbridge investigation go to: https://bespc.com/cases/EVBG

CareDx, Inc. (NASDAQ: CDNA)

On January 25, 2021, the Company sold 1,923,077 shares of its common stock through an underwritten public offering at a public offering price of $91.00 per share.

On October 28, 2021, after the market closed, CareDx released Q3 2021 financial results in which the Company disclosed that the U.S. Department of Justice ("DOJ") had recently served a civil investigatory demand requesting documents in connection with a False Claims Act investigation. The DOJ is investigating business practices related to CareDx's kidney testing and phlebotomy services. The Company also disclosed that it received a subpoena from the U.S. Securities and Exchange Commission ("SEC") for similar issues as well as certain accounting and public reporting practices, and the Company received an information request from an unnamed state agency.

On this news, the Company's share price declined by $19.34 per share, or approximately 27.5%, from $70.34 per share to close at $51.00 per share on October 29, 2021.

For more information on the CareDx investigation go to: https://bespc.com/cases/CDNA

About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com . Attorney advertising. Prior results do not guarantee similar outcomes.

Contact Information:

Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Alexandra B. Raymond, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

CRON:CA,CRON
The Conversation (0)
Cannabis Investing

Ongoing Growth in North America’s Cannabis Space

An article curated by Bazinga highlighted the cannabis market trends from last week. Even though last week was short, the cannabis sector was a busy. The article went on to highlight a number of the cannabis companies looking preparing for their IPOs, among other cannabis related news.

The article went on to highlight the Flowr Corporation as one of numerous companies looking to go public by the end of the year. Flowr’s management team is responsible for the creation and success of MedReleaf, an R&D focused company in the medical cannabis space. In preparation for its RTO in Canada, the company has raised $36 million in financing.

Keep reading...Show less
A hand holding a cannabis leaf in front of the US flag.

Cannabis Round-Up: US DEA Proposes Rescheduling, Canada Ignores Company Tax Concerns

April was a game-changer for the cannabis industry.

After deliberating for almost five months, the Drug Enforcement Administration moved to reschedule cannabis as lawmakers worked to combine the SAFER Banking Act with newly introduced stablecoin legislation.

Meanwhile, controversy struck as legal cannabis was seized in New Mexico, Canada's Federal Budget 2024 was released with no mention of reform to high excise tax rates, and the saga of a once high-end cannabis dispensary finally ended in bankruptcy.

Keep reading...Show less

Goodness Growth Holdings Announces Filing of Application for Summary Determination in Litigation with Verano

Filing reflects Company's belief that Verano's defense against claims of unlawful conduct is without merit –

– Legal filing represents a documentary record and corresponding damages analysis –

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Court gavel in front of national flag of the USA having shadows of cannabis on wooden table.

DEA Submits Proposal to Reschedule Cannabis, Stocks Rally

The Associated Press reported Tuesday (April 30) that the US Drug Enforcement Administration (DEA) was on the cusp of rescheduling cannabis from a Schedule I substance, the same category as heroin and methamphetamines, to Schedule III.

The Department of Health and Human Services suggested cannabis be reclassified on August 29, 2023, and the DEA has been deliberating on the decision for months, urged by lawmakers to heed the recommendation.

According to the report, Attorney General Merrick Garland was scheduled to submit the proposal to the White House Office of Management and Budget on Tuesday afternoon. President Biden has been vocal about his stance on this issue and has urged the Attorney General to expedite the process, suggesting his readiness to move forward once the proposal reaches his desk.

Keep reading...Show less

Goodness Growth Provides CREAM & Fire Updates

Josh Rosen to shed Interim title and become Chief Executive Officer; Company provides other key personnel updates –

– Company receives a short-term extension of the maturity date on its credit facility –

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Goodness Growth Holdings to Release First Quarter 2024 Results on May 7, 2024

Goodness Growth Holdings, Inc. ("Goodness Growth" or the "Company") (CSE: GDNS; OTCQX: GDNSF), a cannabis company committed to providing safe access, quality products and great value to its customers, today announced that it will release its financial results for its first quarter ended March 31, 2024 on Tuesday, May 7, 2024 after the market closes.

Goodness Growth management will host a conference call with the investment community that day, Tuesday, May 7, 2024 at 4:30 p.m. ET (3:30 p.m. CT) to discuss its results. Interested parties may attend the conference call by dialing 1-800-715-9871 (Toll-Free) (US and Canada) or 1-646-307-1963 (Toll) (International) and referencing conference ID number 3718174.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Cronos Group Inc. to Hold Virtual 2024 Annual Meeting of Shareholders

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos" or the "Company") will hold its 2024 Annual Meeting of Shareholders on Thursday, June 20, 2024, at 11:00 a.m. ET.

Cronos will be conducting the meeting in a virtual-only format via live audio webcast. Registered shareholders and duly appointed proxyholders will have an equal opportunity to participate in the 2024 Annual Meeting online regardless of their geographic location, including a chance to ask questions and vote.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×